tiprankstipranks
Blurbs

Robert W. Baird Maintains Their Buy Rating on Syneos Health (SYNH)

In a report issued on January 19, Eric Coldwell from Robert W. Baird maintained a Buy rating on Syneos Health (SYNHResearch Report), with a price target of $132.00. The company’s shares closed last Thursday at $91.59.

According to TipRanks.com, Coldwell is a 5-star analyst with an average return of 13.5% and a 61.5% success rate. Coldwell covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, AmerisourceBergen, and Cardinal Health.

Currently, the analyst consensus on Syneos Health is a Strong Buy with an average price target of $115.00, representing a 27.8% upside. In a report issued on January 23, Jefferies also maintained a Buy rating on the stock with a $118.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $104.18 and a one-year low of $69.53. Currently, Syneos Health has an average volume of 560.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Syneos Health, Inc. provides outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded on August 13, 2010 and is headquartered in Morrisville, NC.

Read More on SYNH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More